Cipla, a global pharmaceutical company, has signed an agreement with
Salix Pharmaceuticals, Inc., a US-based speciality pharmaceutical
company. Under the agreement, Cipla has granted Salix exclusive rights
under certain patent applications in the ‘Rifaximin Complexes’ patent
family controlled by Cipla. Real Time News & Trading Trends Keep Liking Epic Research Private Limited
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co
No comments:
Post a Comment